Disease-modifying drugs in pediatric patients with multiple sclerosis

Bykova O.V.; Nankina I.A.; Drozdova I.M.; Kvasova O.V.; Batysheva T.T.; Boĭko A.N.

doi:https://doi.org/10.17116/jnevro20161162244-53

Close metadata

Recommended articles:

Hormonal contraception methods and multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

Epidemiology of multiple sclerosis in the city of Novosibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127

Results of the All-Russian consensus conference on complications in bariatric surgery. Endoscopic Surgery. 2025;(1):15-24

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68

Pharmacological pain management in pediatric intensive care. Russian Journal of Pain. 2025;(1):56-61

Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77

Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry. Russian Cardiology Bulletin. 2025;(1):22-38

Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coronary intervention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200

Influence of griseofulvin on intestinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):185-190

Abstract:

The vast majority of therapies are being evaluated and introduced for the treatment of adult multiple sclerosis (MS). A role of these drugs in the management of pediatric MS has yet to be defined both in Russia and in the whole world. Despite the fact that today the study of new drugs in the pediatric population have included in routine practices of the big pharmaceutical agencies, such as FDA and EMA, recommendations for the treatment of pediatric patients with MS are based not so much on a long period of systematic clinical research, but on professional consensus of international expert associations, in particular, the International pediatric multiple sclerosis study group (IPMSSG). The clinical trials include the small number of patients which is not comparable to those conducted in adults. Therefore, there is a need for study designs for assessment of efficacy and safety of the drugs for MS treatment in children and adolescents. The authors present the IPMSSG concept on the treatment of pediatric MS taking into account peculiarities of the Russian legislation and experience of national experts.

Keywords:

multiple sclerosis

pediatric patients

therapy

DMT

Authors:

Bykova O.V.

Detskaia klinicheskaia psikhonevrologicheskaia bol'nitsa #18, kabinet detskogo rasseiannogo skleroza, Moskva

Nankina I.A.

Detskaia klinicheskaia psikhonevrologicheskaia bol'nitsa #18, kabinet detskogo rasseiannogo skleroza, Moskva

Drozdova I.M.

Pirogov Russian National Research Medical University, Moscow

Kvasova O.V.

Pirogov Russian National Research Medical University, Moscow

Batysheva T.T.

Poliklinika vosstanovitel'nogo lecheniia #7

SPIN RSCI: 2364-1600
Scopus AuthorID: 16051959600
ORCID: 0000-0003-0928-2131

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

Close metadata

References:

Duquette R, Murray TJ, Pleines J et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr. 1987;111:359-363. doi: 10.1016/s0022-3476(87)80454-7.
Boiko A, Vorobeychik G, Paty D, Devonshire V and Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59:1006-1010. doi: 10.1212/wnl.59.7.1006.
Ghezzi A, Deplano V, Faroni J et al. Multiple sclerosis in childhood: clinical features of 149 cases. Multiple sclerosis (Houndmills, Basingstoke, England). 1997;3:43-46. doi: 10.1177/135245859700300105.
Sindern E, Haas J, Stark E and Wurster U. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand. 1992;86:280-284. doi: 10.llll/j.1600-0404.1992.tb05086.x.
Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Multiple Sclerosis (Houndmills, Basingstoke, England). 2009;15:627-631. doi: 10.1177/1352458508101933.
Pohl D, Waubant E, Banwell B et al. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007;68:54-65. doi: 10.1212/01 .wnl.0000259407.40023 .ab.
Yeh EA, Chitnis T, Krupp L et al. Pediatric multiple sclerosis. Nat Rev Neurol. 2009;5:621-631. doi: 10.1038/nrneurol.2009.158.
Kuntz NL, Chabas D, Weinstock-Guttman B et al. Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother. 11:505-520. doi: 10.1517/14656560903 527218.
Ghezzi A, Banwell B, Boyko A et al. The management of multiple sclerosis in children: a European view. Multiple Sclerosis fib. 2009;1258-1267. doi: 10.1177/1352458510175568.
Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-178. doi: 10.1212/wnl.58.2.169.
Krupp LB, Banwell V,Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68:7-12. doi: 10.1212/01.wnl.0000259422.44235.a8.
Gorman MP, Healy VS, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Archives of neurology. 2009;66:54-59. doi: 10.1001/archneurol.2008.505.
Amato MP, Goretti B, Ghezzi A et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008; 70: 1891-1897. doi: 10.1212/01 .wnl.0000312276.23177.fa.
MacAllister WS, Belman AL, Milazzo M et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology. 2005;64:1422-1425. doi: 10.1212/01 .wnl.0000158474.24191.bc.
Amato MP, Goretti B, Ghezzi A et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 75:1134-1140. doi: 10.1212/wnl.0b013e3181f4d821.
Renoux C, Vukusic S, Mikaeloff Y et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356:2603-2613. doi: 10.1056/nejmoa067597.
Simone IL, Carrara D, Tortorella C et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002;59:1922-1928. doi: 10.1212/01 .wnl.0000036907.37650.8e/
Trojano M, Paolicelli D, Bellacosa A, Fuiani A, Cataldi S, Di Monte E. Atypical forms of multiple sclerosis or different phases of a same disease? Neurol Sci. 2004;25(suppl 4):323-325. doi: 10.1007/sl0072-004-0334-0.
Waubant E, Chabas D, Okuda DT et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009;66:967-971. doi: 10.1001/archneurol.2009.135.
Yeh EA, Weinstock-Guttman B, Ramanathan M et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009;132:3392-3400. doi: 10.1093/brain/awp278.
Waubant E, Hietpas J, Stewart T et al. Interferon beta-la in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001;32:211-213. doi: 10.1055/s-2001-17370.
Mikaeloff Y, Moreau T, Debouverie M et al. Interferon-beta treatment in patients with chMdhood-onset multiple sclerosis. J Pediatr. 2001;139:443-446. doi: 10.1067/mpd.2001.117004.
Ghezzi A, Amato MP, Capobianco M et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis (Houndmills, Basingstoke, England). 2005;11:420-424. doi: 10.1191/1352458505msl206oa.
Portaccio E, Goretti B, Lori S et al. The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 2009;15:620-626. doi: 10.1177/1352458508101950.
Banwell B, Reder AT, Krupp L et al. Safety and tolerability of interferon beta-lb in pediatric multiple sclerosis. Neurology. 2006;66:472-476. doi: 10.1212/01 .wnl.0000198257.52512.1a.
Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-la. Neurology. 2005;64:888-890. doi: 10.1212/01.wnl.0000153570.33845.6a.
Tenembaum SN and Segura MJ. Interferon beta-la treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67:511-513. doi: 10.1212/01.wnl.000023U37.24467.aa.
Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003;34:120-126. doi: 10.1055/s-2003-41274.
Ghezzi A, Pozzilli C, Grimaldi LM et al. Safety and efficacy of natal izumab in children with multiple sclerosis. Neurology. 2009;75:912-917. doi: 10.1212/wnl.0b013e3181flldaf.
Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. Journal of child neurology. 2011;26:675-682. doi: 10.1177/0883073810395141.
Ghezzi A, Banwell B, Boyko A et al. The management of multiple sclerosis in children: a European view. Multiple Sclerosis. 2010;16:1258-1267. doi: 10.1177/0883073810395141.
Yeh EA, Waubant E, Krupp LB et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Archives of neurology. 2010;68:437. doi: 10.1001/archneurol.2010.325.
Bykova OB, Maslova OI, Guseva MP i dr. Rasseyannyi skleroz u detei i podrostkov: istoriya izucheniya problemy i sovremennyi opyt immunomoduliruyushchego lecheniya. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2004;104:4-10. doi: 10.1016/s0303-8467(02)00039-2.
Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia S, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006;67:258-262. doi: 10.1212/01.wnl.0000224757.69746.fb_.
Callen DJ, Shroff MM, Branson HM et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology. 2009;72:968-973. doi: 10.1212/01.wnl.0000338630.20412.45.
Callen DJ, Shroff MM, Branson HM et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology. 2009;72:961-967. doi: 10.1212/01 .wnl.0000338629.01627.54.
Mikaeloff Y, Adamsbaum C, Husson B et al. MR1 prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004;127:1942-1947. doi: 10.1093/brain/awh218_.
Florio S, Maniscalco GT. Improvement of visual acuity in patients with severe visual loss affected by multiple sclerosis treated with natalizumab: a case report. Neurol Sci. 31:3;325-327. doi: 10.1007/s 10072-010-0349-7.
Huppke P, Stark W, Zurcher C, Huppke B, Bruck W, Gartner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008;65:1655-1658. doi: 10.100 l/archneur.65.12.1655.
Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol. 2009;13:67-71. doi: 10.1016/j.ejpn.2008.01.007.
Hawker K, O’Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of neurology. 2009;66:460-471. doi: 10.1002/ana.21867.
Cohen BA, Khan O, Jeffery DR et al. Identifying and treating patients with suboptimal responses. Neurology. 2004;63:33-40. doi: 10.1212/wnl.63.12 suppl_6.s33.
Freedman MS, Cohen B, Dhib-Jalbut S et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin. 2009;25:10:2459-2470. doi: 10.1185/03007990903158364.
Rio J, Nos C, Tintore M et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol. 2002;52:400-406. doi: 10.1002/ana. 10290.
Polman CH, Bertolotto A, Deisenhammer F et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9:740-750. doi: 10.1016/s 1474-4422( 10)70103-4.
Makhani N, Gorman MP, Branson HM, Stazzone L, Vanwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009;72:2076-2082. doi: 10.1212/wnl.0b01 zez 181 a8164c.
Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology. 2008;71:1090-1093. doi: 10.1212/01 .wnl.0000326896.66714.ae.
Chabas D, Ness J, Belman A et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology. 74:399-405. doi: 10.1212/wnl.0b01 zez 181 ce5db0.
McLaughlin KA, Chitnis T, Newcombe J et al. Age-dependent V cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009;183;6:4067-4076. doi: 10.4049/jimmunol.0801888.
Chitnis T, Bar-Or A. Pediatric MS: Biological presentation and research up-date:157-168.Demyelinating Disorders of ihe Central Nervous System in Childhood. Cambridge Medicine.2011. doi: 10.1017/cbo9780511974373.016.
Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M. Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol. 2011;7:109-122. doi: 10.1038/nrneurol.2010.198.
Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. The New England journal of medicine. 2006;354:899-910. doi: 10.1056/nejmoa044397.
Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-la for relapsing multiple sclerosis. The New England journal of medicine. 2006;354:911-923. doi: 10.1056/nejmoa044396.
Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Annals of neurology. 2010;68:295-303. doi: 10.1002/ana.22128.
Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5:e1000363. doi: 10.1371/journal.ppat. 1000363.
Knowles WA, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003;71:115-123. doi: 10.1371 /journal.ppat. 1000363.
Voloshina N.P., Egorkina O.V. Proekt protokola lecheniya pediatricheskogo rasseyannogo skleroza. Mezhdunarodnyi nevrologicheskii zhurnal. 2012;8:1-54.
Carson KR, Focosi D, Major EO et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. The lancet oncology. 2009;10:816-824. doi: 10.1016/s 1470-2045(09)70161-5.
Kornek B, Bernert G, Rostasy K et al. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics. 2011;42:7-12. doi: 10.1055/s-0q31-1275345.
Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. The New England journal of medicine. 362:387-401. doi: 10.10s6/nejmoa0909494.
Weiner HL, Mackin GA, Orav EJ et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993;43:910-918. doi: 10.1212/wnl.43.5.910.
Baca V, Lavalle C, Garcia R et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatry lupus. J Rheumatol. 1999;26:432-439. doi: 10.1016/s0188-4409(01)00366-6.
Yildirim-Toruner S, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011;127:303-312; quiz 13-14. doi: 10.1016/j jaci.2010.12.1087.
Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs. 2006;66:1191-1207. doi: 10.2165/00003495-200666090-00003.
Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. The New England journal of medicine. 2008;358:676-688. doi: 10.1056/nejmoa0706383.
Tzaribachev N, Koetter 1, Kuemmerle-Deschner JB, Schedel J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases journal. 2009;2:6609. doi: 10.4076/1757-1626-2-6609.
Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG. Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:10907-10912. doi: 10.1073/pnas.l 832725100.
Chitnis T, Tenembaum S, Banwell B et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Multiple Sclerosis. 2012;18:l:116-127. doi: 10.1177/1352458511430704.
Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol. 2002;9:557-563. doi: 10.1046/j.1468-__1331.2002.00501.x.
Tintore M, Rovira A, Martinez MJ et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol. 2000;21(4):702-706. doi: 10.1177/135245850100700603.
Suponeva N.A., Piradov M.A. Vnutrivennaya immunoterapiya v nevrologii. M.: Goryachaya liniya telekom. 2013.